By 2027, the global gene therapy market is estimated to reach a staggering value of $6.6B. With the number of successfully approved gene therapies increasing, the sector has moved from hype to hope. At the heart of gene therapy lie viral vectors, which are used to transport a gene into a target cell. Here we explore the current bottleneck in viral vector production, why viral vectors still outshine non-viral vector solutions, and what we can expect in the future.
The gene therapy field is gaining momentum. Investments are pouring in. The FDA is estimating that by 2025 it will approve between 10 and 20 cell and gene therapy products every year. This shows that a treatment, which started out as a hype, is now a real hope, says Ratish Krishnan, Associate Director of Cell and Gene Therapy Bioprocessing at MilliporeSigma*.
Today, a number of treatments have been approved, such as Spark Therapeutics LUXTURNA, the first FDA approved in vivo gene therapy, or Novartis Zolgensma, which gained US approval in 2019 and European approval in March 2020.
One of the key ingredients of gene therapies is the viral vector, which is used to transfer a gene of interest into a target cell. The most commonly used vector is that of the adeno-associated virus (AAV). But the manufacturing of viral vectors and scaling up their production remain difficult.
In upstream development, one challenge is the way viral vectors are produced. In a process called transient transfection, plasmids carrying the DNA of interest are introduced into host cells that will produce the viral vectors.
But host cells are commonly grown in adherent cell cultures, which are usually harder to reproduce at a large scale. So to scale-up and achieve high titers of virus particles, researchers are working on growing cells in suspension using large bioreactors instead.
We are facing several challenges at the moment and that is what keeps us on our toes, Krishnan adds. In upstream development, there is a desire to move towards suspension. Most processes use transient transfection methods using plasmids and the transfection step at a production scale of 500L or 2000L is extremely challenging.
In downstream development, researchers are studying the purity of capsids. The capsid is the protective shell of the virus enclosing the gene of interest. Related to this is an important discussion on the purity of viral vectors.
When you produce vectors, you will generally have a population of empty capsids, which is the viral AAV assembly without the genetic material inside, or partially-full capsids with only part of the DNA inside, Krishnan explains. We have to better understand the role of empty capsids inside the body. Are they needed as immune decoys or are they strictly considered impurities? In theory, you only need the ones with all the DNA inside, the full capsids.
But researchers have yet to discover the correct percentage of full capsids in a drug substance or product, Krishnan says. We dont have the answer yet. Typically, the strategy leans towards the enrichment of a percentage of full capsids as high as possible, while taking into account the data from clinical trials.
Questions about purity are difficult to answer because there is little or no regulatory guidance. For instance, compared to monoclonal antibodies (mAbs) for which the regulatory environment is well understood, the regulatory landscape for gene therapies remains largely unclear.
Through decades of research, mAb production also works through well-established and standardized platforms, whereas viral vectors are still in their infancy and cannot be produced using platform technologies yet although much is being done in this field and they are catching up fast.
Because of their longstanding history, we already have a lot of knowledge and research about mAbs, Krishnan explains. Lets say I want to start a biotech company or a CDMO that develops mAbs. I can rely on existing templates and get up and running much quicker than if I were developing viral vectors.
AAVs come in many different serotypes distinguishable strains which impact platform development. The scale-up is also challenging since the indications can be strikingly contrasting. For example, ocular indications need smaller viral drug substances compared to a muscular indication.
Manufacturing mAbs is better understood than manufacturing viral vectors. Viruses are a whole lot bigger and can be more complex than antibodies. While antibodies usually have a size around 10 nm, AAVs measure around 20nm and Lentiviruses around 100nm in size. Not only are antibodies produced at a larger scale than viral vectors, but their scalability is also more predictable due to the established platform technologies.
Despite these challenges, the increase in popularity, investments flooding in, and the promise of essential cures have led to a bottleneck in viral vector production for gene therapies. But many companies working in the gene therapy field are small or emerging biotechs that do not have the necessary resources and expertise in-house to tackle the challenges of viral vector production.
Lacking the facilities to do it themselves, small and emerging biotechs therefore turn to experienced contract development and manufacturing organizations (CDMOs), such as Merck BioReliance, to produce their gene therapies.
There are only a handful of CDMOs that have the capability and expertise to take on the complexities of gene therapy projects, Krishnan says. But there is currently a bottleneck in manufacturing slots. Manufacturing facilities can only work 24 hours a day, and if you are a small company and a CDMO has other clients waiting in line before you to have their therapies manufactured, you have no other option but to wait.
The problem with waiting, of course, is that the biotech runs the risk of falling behind its competition. Krishnan emphasizes, time is of the essence in gene therapy. There is no silver medal for developing a therapy for the same indication.
The key, says Krishnan, lies in much planning and close engagement with the CDMO partner. Biotechs should do an analysis of what they can perform in-house versus what they have to outsource early on. Engaging a CDMO is the route you want to take.
With decades of experience, Merck can support its biotech sponsors all the way to the clinic. We are big on the concept of integrated solutions, Krishnan explains. From clone to clinic to commercialization, Merck has the expertise, knowledge network, product, and services to help guide any customer to the finish line. We have the CDMO expertise with BioReliance, with testing services, gene therapy expertise, and regulatory support.
To circumvent the manufacturing bottleneck for viral vectors, some biotechs are looking at non-viral vector solutions for gene therapies. While traditional gene therapies use a viral vector, like AAV, to transfer a gene of interest into the patient, non-viral gene therapy deploys an alternative delivery system for the gene of interest.
Examples for non-viral delivery systems include physical force to deliver the gene through the cell membrane; injecting the gene with a needle into the target region; electroporation, which uses an electric current to produce pores in the cell membrane through which the gene can be inserted into the cell; and chemical vectors, such as lipid-, polymer-, or peptide-based particles.
Nevertheless, viral vectors, such as the AAV, remain the preferred path for most companies. The efficiency of delivery for non-viral vectors remains questionable. This means that there might be reactions in the immune system that get triggered, eliciting a dangerous, adverse response. AAVs, on the other hand, are well-engineered and safe, despite being novel.
Viral vectors have recently demonstrated success, Krishnan adds. Scientists are making advances in the non-viral area of gene therapy but they also come with a unique set of challenges. Questions, such as how do they interact with serum components in the body, how do they involve the immune system before reaching the target tissue, how do they interact with the surfaces of cells, remain.
Despite unaddressed challenges, gene therapy has definitely shifted from being a hope to carrying an expectation. This is reflected in the number of investments pouring into the sector.
Big pharma and biotech companies are heavily investing their resources into gene therapy, Krishnan says. Typically, companies have vaccines or mAbs in their portfolio. Now, gene therapy is becoming a major modality of interest as well.
While we are still far away from reaching the smooth manufacturing processes we have in place for antibodies, many companies are also looking into platform approaches for gene therapy. We would take a quantum leap if we developed a platform approach for upstream and downstream processes. That would significantly reduce the time to the clinic. Platform approaches are definitely being explored, Krishnan adds.
Vendors like Merck are playing a big role in developing fit-for-purpose products for gene therapies, Krishnan says. At the R&D level, researchers are also working on advances in capsid engineering. We already have synthetic capsids, and there are other tremendous advancements in capsid engineering, design, and purity, which are going to continue to evolve.
But, as Krishnan puts it, We are running a marathon at sprint speed. The journey is exciting and challenging, identical to the ride on a rollercoaster, but we are barely even at the tip of the iceberg. There are patients waiting for life-saving treatment, so gene therapies will definitely continue to be in the limelight, and for good reason.
Are you fighting to solve the bottleneck in viral vector production? Get in touch with the expert team at Merck and view their webinar on this topic!
*The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
Images via Shutterstock.com and Elena Resko
Originally posted here:
- Covid-19 Forces Gene Therapy Companies to Shift... - Labiotech.eu - August 3rd, 2020
- The Time for DMD Gene Therapy is Now: A Chat with the MDA - BioSpace - August 3rd, 2020
- Gene therapy reverses memory loss from Alzheimer's in mice - BioNews - August 3rd, 2020
- Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb - Endpoints News - August 3rd, 2020
- World-first gene therapy reverses Alzheimer's memory loss in mice - New Atlas - August 3rd, 2020
- Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis - GlobeNewswire - August 3rd, 2020
- Novartis Teams Up With Sangamo In Brain Gene Therapy Pact - Scrip - August 3rd, 2020
- Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD - GlobeNewswire - August 3rd, 2020
- Of mice and memories: Gene therapy study returns function in Alzheimer's mice - ABC News - August 3rd, 2020
- $3 million per person price tag set on first gene therapy for hemophilia expected ready this fall - Genetic Literacy Project - August 3rd, 2020
- Gene Therapy Market is projected to grow at an annualized rate of 45%, till 2030 - Market Research Posts - August 3rd, 2020
- Spark Therapeutics Recognized for Fourth-straight Year as One of Philadelphia's Best Places to Work by the Philadelphia Business Journal - BioSpace - August 3rd, 2020
- Global Hemophilia Gene Therapy Market is estimated to Experience a Notable Rise in the coming era by Spark Therapeutics, Ultragenyx, Shire PLC,... - August 3rd, 2020
- Hemophilia Gene Therapy Industry Market Analysis by Size, Share, Growth, Application, Segmentation and Forecast to 2025 - Express Journal - August 3rd, 2020
- Dyne Therapeutics Appoints Susanna High as Chief Operating Officer - Business Wire - August 3rd, 2020
- Cell and Gene Therapy Industry Market with manufacturers, Application, regions and SWOT Analysis 2025 - CueReport - August 3rd, 2020
- Investing in Advanced Manufacturing to Support Public Health - FDA.gov - August 3rd, 2020
- Genetic Studies Could Pave the Way to New Pain Treatments - Pain News Network - August 3rd, 2020
- Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector Platform for Next Generation... - August 3rd, 2020
- AZ partners with Daiichi on ADC therapy - BioPharma-Reporter.com - August 3rd, 2020
- Covid-19 Forces Gene Therapy Companies to Shift... - Labiotech.eu - August 2nd, 2020
- Getting gene therapy to the brain | Penn Today - Penn Today - August 2nd, 2020
- Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis - GlobeNewswire - August 2nd, 2020
- Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb - Endpoints News - August 2nd, 2020
- Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative... - August 2nd, 2020
- World-first gene therapy reverses Alzheimer's memory loss in mice - New Atlas - August 2nd, 2020
- Gene Therapy Market is projected to grow at an annualized rate of 45%, till 2030 - Market Research Posts - August 2nd, 2020
- Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD - BioSpace - August 2nd, 2020
- UW researchers devise approach to treat rare, incurable form of blindness - University of Wisconsin-Madison - August 2nd, 2020
- Gene Therapy for Inherited Genetic Disorders Market size in terms of volume and value 2019-2025 - Market Research Correspondent - August 2nd, 2020
- Cell and Gene Therapy Industry Market with manufacturers, Application, regions and SWOT Analysis 2025 - CueReport - August 2nd, 2020
- Genetic Studies Could Pave the Way to New Pain Treatments - Pain News Network - August 2nd, 2020
- Gene Therapy Market Professional Industry Overview 2020 Segmentation and Development Analysis BY 2027 - Science Examiner - August 2nd, 2020
- Greenwich swimmers take the plunge to fight cancer - Greenwich Time - August 2nd, 2020
- Cell and Gene Therapy Market Overview, Growth & Advancement to (2020-2025) - Owned - August 2nd, 2020
- Movers & Shakers, July 31 | BioSpace - BioSpace - August 2nd, 2020
- REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights - Herald-Mail Media - August 2nd, 2020
- Catharpin mom helps raise national awareness for her young sons disease - WDVM 25 - August 2nd, 2020
- The Time for DMD Gene Therapy is Now: A Chat with the MDA - BioSpace - August 2nd, 2020
- Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD - GlobeNewswire - August 2nd, 2020
- Spinraza-Zolgensma Combination Well-tolerated in Children with SMA... - SMA News Today - August 2nd, 2020
- AZ partners with Daiichi on ADC therapy - BioPharma-Reporter.com - August 2nd, 2020
- Vineti and EVERSANA form strategic alliance to advance patient-centered services and supply chain automation for regenerative medicine - PRNewswire - August 2nd, 2020
- Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results - GlobeNewswire - August 2nd, 2020
- Expression Therapeutics Announces Bill Swaney as VP of Manufacturing and the Construction of Cell and Gene Therapy Manufacturing - Yahoo Finance - August 2nd, 2020
- REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights - PRNewswire - August 2nd, 2020
- Global Gene Therapy Market Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2025 - Research Newspaper - August 2nd, 2020
- Cell and Gene Therapy Tools, and Reagents: Global Markets - PRNewswire - August 1st, 2020
- Gene Therapy Beats the Blood-Brain Barrier To Cure Cat Disease - Technology Networks - July 31st, 2020
- Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD - PharmiWeb.com - July 31st, 2020
- Expression Therapeutics Announces Bill Swaney as VP of Manufacturing and the Construction of Cell and Gene Therapy Manufacturing - BioSpace - July 31st, 2020
- CPI, the Cell and Gene Therapy Catapult and MicrofluidX announce development of technology to rapidly scale up cell and gene therapy manufacture -... - July 31st, 2020
- Navigating Complexity in Oncology Cell and Gene Therapy Clinical Trials - Clinical OMICs News - July 31st, 2020
- Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results - BioSpace - July 31st, 2020
- Genprex CEO Participates in a Second-Round Live Interview on the Big Biz Show - Business Wire - July 31st, 2020
- Ongoing Trial Assesses New Anti-VEGF Gene Therapy Injection for nAMD - MD Magazine - July 30th, 2020
- Increasing Government Investments and Favorable Policies to Aid the Growth of the Cancer Gene Therapy Market2020 - Owned - July 30th, 2020
- Cell and Gene Therapy Tools, and Reagents: Global Markets - cnweekly - July 30th, 2020
- Consumer Demand for Eco-friendly Products Set to Boost the Prospects of the Cancer Gene Therapy Market2020 - Owned - July 30th, 2020
- FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL - FDA.gov - July 29th, 2020
- Covid 19 Analysis On Personalized Gene Therapy Treatments for Cancer Market 2020 Top 10 Countries Exclusive Data, Demand, Share and Growth Analysis by... - July 29th, 2020
- Gene therapy - Mayo Clinic - July 29th, 2020
- gene therapy | Description, Uses, Examples, & Safety ... - July 29th, 2020
- Over 100 million cash boost to manufacture millions of doses of COVID-19 vaccine - GOV.UK - July 29th, 2020
- AGC to Complete the Acquisition of MolMed on July 31, 2020 - NBC Right Now - July 29th, 2020
- Strokes often deadly but gene therapy offers hope to rebuild critically damaged brain cells - Genetic Literacy Project - July 29th, 2020
- Gene Therapy for Age-related Macular Degeneration Market 2020 | Present Scenario and Growth Prospects 2025 - Bulletin Line - July 29th, 2020
- ZMR Revises Gene Therapy Market Forecast, as COVID-19 Continues to Expand Quickly Across the Globe - Market Research Posts - July 29th, 2020
- Encoded Therapeutics bags $135M to push 'precision gene therapy' into the clinic - FierceBiotech - July 28th, 2020
- GV's David Schenkein comes in to help mentor and bankroll a gene therapy 2.0 player, intrigued by their 'science heavy' approach to conquering... - July 28th, 2020
- Few CMOs are equipped to manufacture cell and gene therapies - Pharmaceutical Technology - July 28th, 2020
- Thermo Fisher Launches Cell And Gene Therapy Mfg. Offering - Contract Pharma - July 28th, 2020
- 2020 Growth: Gene Therapy Market 2020 Research on Import-Export Details, Business Standards and Forecast to 2025 - Owned - July 28th, 2020
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of... - July 28th, 2020
- Apic Bio Announces Formation of Scientific Advisory Board - Business Wire - July 28th, 2020
- Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market COVID -19 Impact Analysis | Size, Trends Analysis, Region, Demands and... - July 28th, 2020
- Gene Therapy Market Size Analysis and Growth (2020-2025) Owned - Owned - July 28th, 2020
- Global Tissue Engineering Gene Therapy Market 2020 Coronavirus (COVID-19) Updated Analysis By Product (Autologous cell therapy, Allogeneic cell... - July 28th, 2020
- Cell and Gene Therapy Tools, and Reagents: Global Markets - Yahoo Finance - July 28th, 2020
- 'Gene therapy engine' Forge debuts with $40M and Tim Miller at the helm - FierceBiotech - July 28th, 2020